Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of EDP-305 in healthy males
NCT03748628Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EDP-305 in Nonalcoholic steatohepatitis (NASH), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration (Cmax) of EDP-305 up to 9 days, Area Under the Curve (AUC) of EDP-305 up to 9 days and 1 more. Started Oct 2018; status: completed.
02
Drugs
EDP-305
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03748628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748628.